These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 18487569)

  • 1. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.
    Heinrich S; Pestalozzi BC; Schäfer M; Weber A; Bauerfeind P; Knuth A; Clavien PA
    J Clin Oncol; 2008 May; 26(15):2526-31. PubMed ID: 18487569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial.
    Heinrich S; Schäfer M; Weber A; Hany TF; Bhure U; Pestalozzi BC; Clavien PA
    Ann Surg; 2008 Dec; 248(6):1014-22. PubMed ID: 19092346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
    Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
    BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
    Motoi F; Satoi S; Honda G; Wada K; Shinchi H; Matsumoto I; Sho M; Tsuchida A; Unno M;
    J Gastroenterol; 2019 Feb; 54(2):194-203. PubMed ID: 30182219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
    Motoi F; Ishida K; Fujishima F; Ottomo S; Oikawa M; Okada T; Shimamura H; Takemura S; Ono F; Akada M; Nakagawa K; Katayose Y; Egawa S; Unno M
    Ann Surg Oncol; 2013 Nov; 20(12):3794-801. PubMed ID: 23838925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.
    Golcher H; Brunner TB; Witzigmann H; Marti L; Bechstein WO; Bruns C; Jungnickel H; Schreiber S; Grabenbauer GG; Meyer T; Merkel S; Fietkau R; Hohenberger W
    Strahlenther Onkol; 2015 Jan; 191(1):7-16. PubMed ID: 25252602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).
    Maurel J; Sánchez-Cabús S; Laquente B; Gaba L; Visa L; Fabregat J; Povés I; Roselló S; Díaz-Beveridge R; Martín-Richard M; Rodriguez J; Sabater L; Conill C; Cambray M; Reig A; Ayuso JR; Valls C; Ferrández A; Bombí JA; Ginés A; García-Albéniz X; Fernández-Cruz L
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):935-943. PubMed ID: 30225601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.
    Reni M; Balzano G; Zanon S; Zerbi A; Rimassa L; Castoldi R; Pinelli D; Mosconi S; Doglioni C; Chiaravalli M; Pircher C; Arcidiacono PG; Torri V; Maggiora P; Ceraulo D; Falconi M; Gianni L
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):413-423. PubMed ID: 29625841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.
    Ielpo B; Duran H; Diaz E; Fabra I; Caruso R; Ferri V; Malavé L; Hidalgo M; Alvarez R; Plaza C; Quijano Y; Vicente E
    Eur J Surg Oncol; 2016 Sep; 42(9):1394-400. PubMed ID: 26899943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer.
    Sahora K; Kuehrer I; Eisenhut A; Akan B; Koellblinger C; Goetzinger P; Teleky B; Jakesz R; Peck-Radosavljevic M; Ba'ssalamah A; Zielinski C; Gnant M
    Surgery; 2011 Mar; 149(3):311-20. PubMed ID: 20817204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
    Reni M; Balzano G; Aprile G; Cereda S; Passoni P; Zerbi A; Tronconi MC; Milandri C; Saletti P; Rognone A; Fugazza C; Magli A; Di Muzio N; Di Carlo V; Villa E
    Ann Surg Oncol; 2012 Jul; 19(7):2256-63. PubMed ID: 22237835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies.
    Andriulli A; Festa V; Botteri E; Valvano MR; Koch M; Bassi C; Maisonneuve P; Sebastiano PD
    Ann Surg Oncol; 2012 May; 19(5):1644-62. PubMed ID: 22012027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer.
    Sahora K; Kuehrer I; Schindl M; Koelblinger C; Goetzinger P; Gnant M
    World J Surg; 2011 Jul; 35(7):1580-9. PubMed ID: 21523499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer.
    Lee KH; Chie EK; Im SA; Kim JH; Kwon J; Han SW; Oh DY; Jang JY; Kim JS; Kim TY; Bang YJ; Kim SW; Ha SW
    Cancer Res Treat; 2021 Oct; 53(4):1096-1103. PubMed ID: 33421976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.
    Seufferlein T; Uhl W; Kornmann M; Algül H; Friess H; König A; Ghadimi M; Gallmeier E; Bartsch DK; Lutz MP; Metzger R; Wille K; Gerdes B; Schimanski CC; Graupe F; Kunzmann V; Klein I; Geissler M; Staib L; Waldschmidt D; Bruns C; Wittel U; Fichtner-Feigl S; Daum S; Hinke A; Blome L; Tannapfel A; Kleger A; Berger AW; Kestler AMR; Schuhbaur JS; Perkhofer L; Tempero M; Reinacher-Schick AC; Ettrich TJ
    Ann Oncol; 2023 Jan; 34(1):91-100. PubMed ID: 36209981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy.
    Sherman WH; Hecht E; Leung D; Chu K
    Oncologist; 2018 Jan; 23(1):4-e10. PubMed ID: 29212734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
    Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
    Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
    Landry J; Catalano PJ; Staley C; Harris W; Hoffman J; Talamonti M; Xu N; Cooper H; Benson AB
    J Surg Oncol; 2010 Jun; 101(7):587-92. PubMed ID: 20461765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.